NO20022584L - Kombinerte midler for behandling av glaukom - Google Patents

Kombinerte midler for behandling av glaukom

Info

Publication number
NO20022584L
NO20022584L NO20022584A NO20022584A NO20022584L NO 20022584 L NO20022584 L NO 20022584L NO 20022584 A NO20022584 A NO 20022584A NO 20022584 A NO20022584 A NO 20022584A NO 20022584 L NO20022584 L NO 20022584L
Authority
NO
Norway
Prior art keywords
glaucoma
treatment
combined agents
active ingredients
prostaglandins
Prior art date
Application number
NO20022584A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022584D0 (no
Inventor
Tomihisa Yokohama
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20022584D0 publication Critical patent/NO20022584D0/no
Publication of NO20022584L publication Critical patent/NO20022584L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO20022584A 1999-12-01 2002-05-31 Kombinerte midler for behandling av glaukom NO20022584L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34152499 1999-12-01
JP2000078769 2000-03-21
PCT/JP2000/008545 WO2001039805A1 (en) 1999-12-01 2000-12-01 Concomitant drugs for treating glaucoma

Publications (2)

Publication Number Publication Date
NO20022584D0 NO20022584D0 (no) 2002-05-31
NO20022584L true NO20022584L (no) 2002-07-29

Family

ID=26576988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022584A NO20022584L (no) 1999-12-01 2002-05-31 Kombinerte midler for behandling av glaukom

Country Status (22)

Country Link
US (4) US7307096B2 (de)
EP (3) EP1234582B1 (de)
JP (1) JP4000505B2 (de)
KR (3) KR20040045028A (de)
CN (3) CN1263512C (de)
AT (1) ATE332145T1 (de)
AU (1) AU773110B2 (de)
BR (1) BR0015980A (de)
CA (1) CA2392804C (de)
CZ (1) CZ20021829A3 (de)
DE (1) DE60029242T2 (de)
ES (1) ES2267586T3 (de)
HK (1) HK1047239B (de)
HU (1) HUP0204049A3 (de)
IL (2) IL149444A0 (de)
MX (1) MXPA02005505A (de)
NO (1) NO20022584L (de)
NZ (1) NZ518930A (de)
PL (1) PL201783B1 (de)
RU (4) RU2002114335A (de)
TW (1) TWI290470B (de)
WO (1) WO2001039805A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4261912B2 (ja) * 2001-04-19 2009-05-13 テイカ製薬株式会社 薬剤および薬剤キット
TW200305424A (en) * 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
US20050119299A1 (en) * 2002-03-08 2005-06-02 Sankyo Company, Limited Ophthalmic solutions containing tetrazole derivatives
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
WO2005018646A1 (ja) * 2003-08-21 2005-03-03 Sucampo Ag 眼科用組成物
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2005079809A1 (ja) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. 澄明なラタノプロスト点眼液
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
RU2339384C1 (ru) * 2007-10-18 2008-11-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Вискоэластик для защиты интраокулярных тканей
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
RU2411946C1 (ru) * 2009-07-06 2011-02-20 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Вископротектор для защиты интраокулярных тканей
CA2798923A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
US9259409B2 (en) 2011-01-24 2016-02-16 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR101327267B1 (ko) 2012-04-26 2013-11-11 한양대학교 에리카산학협력단 엔드이펙터용 구동력 전달장치
JP6686023B2 (ja) * 2014-11-25 2020-04-22 エキシモア・リミテッドＥｘｉｍｏｒｅ Ｌｔｄ． 生物活性剤または生物活性剤類を送達する組成物および方法
MX2017007572A (es) * 2014-12-12 2018-02-09 Kowa Co Composicion acuosa.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619370A (en) 1969-04-21 1971-11-09 Frosst & Co Charles E Microbial reduction of thiadiazoles
JPS536156B2 (de) 1972-10-30 1978-03-04
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
DE3568431D1 (en) * 1984-12-12 1989-04-06 Merck & Co Inc Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
JP2610619B2 (ja) * 1987-07-22 1997-05-14 エーザイ株式会社 高眼圧症治療用点眼剤
JPS6426518U (de) 1987-08-11 1989-02-15
ES2317964T5 (es) 1988-09-06 2015-02-20 Pfizer Health Ab Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
DE58909862D1 (de) 1988-09-09 1999-12-16 Klaus Draenert Hüftgelenksprothese
EP0375299A1 (de) * 1988-12-19 1990-06-27 Merck & Co. Inc. Mischungen von ACE- und CA-Inhibitoren zur Behandlung von Glaucoma
US5273976A (en) * 1989-04-06 1993-12-28 Sankyo Company, Limited Ocular hypotensive agents
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
IL104648A0 (en) 1992-02-13 1993-06-10 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a prostaglandin or prostaglandin derivative
EP0625903B1 (de) * 1992-02-21 1998-08-12 Alcon Laboratories, Inc. Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5889020A (en) * 1994-02-08 1999-03-30 Ciba Vision Corporation Treatment of normotensive glaucoma with angiotensin II antagonists
ATE206050T1 (de) * 1994-03-16 2001-10-15 Sankyo Co Okulares hypotensium
CA2185524C (en) * 1994-03-16 2006-12-05 Sankyo Company Limited Ocular tension depressant
US5760249A (en) * 1995-08-29 1998-06-02 Merck & Co., Inc. Synthesis of hydroxysulfone and related compounds
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
RU2188013C2 (ru) * 1996-04-05 2002-08-27 Такеда Кемикал Индастриз, Лтд. Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
EP1007028A4 (de) 1997-05-09 2002-06-05 Behandlung von glaukom mit 8-iso-prostaglandinen
PT1186302E (pt) * 1999-06-11 2005-07-29 Sankyo Co Composicao para fazer descer a tensao ocular para administracao topica

Also Published As

Publication number Publication date
DE60029242T2 (de) 2007-07-05
EP1344534A3 (de) 2004-01-02
EP1344534A2 (de) 2003-09-17
RU2004111357A (ru) 2005-09-20
BR0015980A (pt) 2002-11-12
ES2267586T3 (es) 2007-03-16
EP1234582A1 (de) 2002-08-28
ATE332145T1 (de) 2006-07-15
US7307096B2 (en) 2007-12-11
US20050014808A1 (en) 2005-01-20
HK1047239A1 (en) 2003-02-14
US20050043383A1 (en) 2005-02-24
HK1047239B (en) 2006-12-08
IL149444A0 (en) 2002-11-10
JP2001335511A (ja) 2001-12-04
NZ518930A (en) 2003-09-26
PL201783B1 (pl) 2009-05-29
IL149444A (en) 2007-06-17
EP1344535A3 (de) 2004-01-28
WO2001039805A1 (en) 2001-06-07
EP1234582B1 (de) 2006-07-05
RU2299067C2 (ru) 2007-05-20
CN1615879A (zh) 2005-05-18
KR20020058034A (ko) 2002-07-12
MXPA02005505A (es) 2002-09-02
RU2002114335A (ru) 2004-01-10
EP1234582A4 (de) 2003-05-07
US20030040529A1 (en) 2003-02-27
AU1557501A (en) 2001-06-12
DE60029242D1 (de) 2006-08-17
US20080221184A1 (en) 2008-09-11
AU773110B2 (en) 2004-05-20
CA2392804C (en) 2009-02-03
CN1615880A (zh) 2005-05-18
EP1344535A2 (de) 2003-09-17
JP4000505B2 (ja) 2007-10-31
PL355431A1 (en) 2004-04-19
NO20022584D0 (no) 2002-05-31
TWI290470B (en) 2007-12-01
HUP0204049A3 (en) 2006-07-28
CN1263512C (zh) 2006-07-12
RU2004111359A (ru) 2005-09-20
KR20040045028A (ko) 2004-05-31
KR20040045029A (ko) 2004-05-31
HUP0204049A2 (hu) 2003-04-28
KR100607430B1 (ko) 2006-08-02
CZ20021829A3 (cs) 2002-08-14
CN1407903A (zh) 2003-04-02
CA2392804A1 (en) 2001-06-07
RU2004111358A (ru) 2005-09-20

Similar Documents

Publication Publication Date Title
NO20022584L (no) Kombinerte midler for behandling av glaukom
EP1074268A4 (de) Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes mit il-6 antagonisten als aktiven inhaltsstoffen
NO20032360L (no) EP4 reseptor selektive agonister for behandling av osteoporose
DK1734041T3 (da) Inhibitorer for receptoren for ADP-blodplader
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
EP1108435A4 (de) Mittel zur vorbeugung oder behandlung von pankreatitis die il-6 antagonisten als aktive komponente enthalten
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
SI1425277T1 (sl) Seäśninske spojine, aktivne kot vaniloidni receptorski antagonisti za zdravljenje boleäśine
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
PL363168A1 (pl) Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
DE69728585D1 (de) Mittel gegen Juckreiz
NO20016246D0 (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
DE60222168D1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
HU0201394D0 (de)
WO2002078633A8 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
DK1459762T3 (da) Anvendelse af EMP9 til forebyggelse af proliferative organsygdomme
DE60014915D1 (de) Hypoxanthin- und thiohypxanthin-verbindungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application